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Abstract
Cyclooxygenase-derived prostaglandins modulate cardiovascular disease risk. We genotyped 2212
Atherosclerosis Risk in Communities study participants (1,023 incident coronary heart disease
(CHD) cases; 270 incident ischemic stroke cases; 919 non-cases) with available DNA for
polymorphisms in PTGS1 and PTGS2. Using a case–cohort design, associations between genotype
and CHD or stroke risk were evaluated using proportional hazards regression. In Caucasians, the
reduced function PTGS1 −1006A variant allele was significantly more common among stroke cases
compared to non-cases (18.2 versus 10.6%, P = 0.027). In African Americans, the reduced function
PTGS2 −765C variant allele was significantly more common in stroke cases (61.4 versus 49.4%, P
= 0.032). No significant relationships with CHD risk were observed. However, aspirin utilization
appeared to modify the relationship between the PTGS2 G-765C polymorphism and CHD risk
(interaction P = 0.072). These findings suggest that genetic variation in PTGS1 and PTGS2 may be
important risk factors for the development of cardiovascular disease events. Confirmation in
independent populations is necessary.
Ischemic cardiovascular disease is a major public health problem. It is estimated that 1.2 million
Americans will experience an acute coronary heart disease (CHD) event and 0.7 million will
experience an acute stroke event this year.1 Prostaglandin endoperoxide H synthase-1 and -2
(more commonly described as cyclooxygenase (COX)-1 and COX-2, respectively)-derived
prostaglandins are critical regulators of vascular, myocardial, and platelet function, and
alterations in their expression and/or activity can significantly modify risk of cardiovascular
disease events in humans.2–7 Recent evidence demonstrating associations between selective
COX-2 inhibitor utilization and elevated risk of myocardial infarction,3,4 coupled with the
well-known protective effects of low-dose aspirin,5 suggests that the relative contribution of
COX-1 and COX-2-mediated prostaglandin synthesis is an integral mediator of cardiovascular
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homeostasis. Consequently, variation in the genes encoding COX-1 (PTGS1) and COX-2
(PTGS2) may be important modifiers of cardiovascular disease risk.
Numerous genetic polymorphisms in PTGS1 and PTGS2 have been identified and
characterized.8–12 The G-765C polymorphism in the PTGS2 proximal promoter is associated
with lower PTGS2 transcription.9,13,14 Moreover, due to the anti-inflammatory effects
resulting from lower COX-2 expression, the variant −765C allele was associated with
significantly lower risk of prevalent myocardial infarction or ischemic stroke events in a high-
risk Italian population.15 We recently observed that certain non-synonymous polymorphisms
in PTGS1, such as the rare G230S variant, have significantly lower COX-1 metabolic activity
in vitro.12 However, potential associations between PTGS1 and PTGS2 polymorphisms and
risk of incident cardiovascular disease events have not been rigorously evaluated. Our primary
aim was to determine if genetic variation in PTGS1 and PTGS2 was associated with risk of
incident CHD or ischemic stroke events in individuals enrolled in the biethnic Atherosclerosis
Risk in Communities (ARIC) study. An important secondary aim was to determine if this risk
was modified by aspirin utilization.
RESULTS
Study population
Significant baseline differences in various risk factors were observed between CHD and stroke
cases and non-cases included in the cohort random sample, as described previously16
(Supplementary Materials). Incident CHD and stroke cases were significantly older and more
likely to be male, smokers, diabetic, hypertensive, and have abnormal fasting lipid panels
compared to non-cases. Stroke cases were also more likely to be African American and less
likely to report aspirin use at baseline. Aspirin utilization at baseline was significantly lower
in African Americans compared to Caucasians in the cohort random sample (11.4 versus
30.1%, P<0.001), CHD cases (14.2 versus 30.3%, P<0.001), and ischemic stroke cases (13.7
versus 23.8%, P = 0.026), respectively.
PTGS1/PTGS2 genotype
The location and observed race-specific allele frequencies of the six PTGS1 and two PTGS2
polymorphisms evaluated are listed in Table 1. The G-1006A and P17L polymorphisms in
PTGS1 were in near-perfect linkage disequilibrium (LD) in Caucasians (D′ = 0.99, r2 = 0.96),
but not African Americans (D′ = 0.46, r2 = 0.16) (Supplementary Materials). Significant LD
was not observed between the other variants in either racial group (r2<0.02). The allelic
distribution of the PTGS1 P17L polymorphism deviated significantly from Hardy–Weinberg
equilibrium in Caucasians (P = 0.002); however, a disproportionate number of individuals
carrying the −1006A variant allele had missing genotyping data for the P17L polymorphism.
All other polymorphisms were in Hardy–Weinberg equilibrium in both Caucasians and African
Americans (P>0.05).
PTGS1 polymorphisms
In Caucasians, the variant −1006A allele was significantly more common among ischemic
stroke cases compared to cohort random sample non-cases (18.2 versus 10.6%, respectively,
P = 0.027) (Table 2). Presence of at least one −1006A allele was associated with significantly
higher risk of incident ischemic stroke events relative to −1006G homozygotes after adjusting
for age, gender, and study center (model 1, hazard rate ratio (HRR) 1.78, 95% confidence
interval (CI) 1.08–2.92, P = 0.024, q = 0.080) (Table 3). A similar association was observed
after also adjusting for cigarette smoking, diabetes, and hypertension status (model 2, HRR
1.70, 95% CI 0.99–2.93, P = 0.056, q = 0.120); however, this association was not statistically
significant. This relationship was not modified by gender (interaction P = 0.252). A similar
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relationship was also observed with the reconstructed haplotype tagged by both the variant
−1006A and P17L alleles (data not shown). No association between the −1006A allele and risk
of ischemic stroke in African Americans, or risk of CHD in either Caucasians or African
Americans, was observed (Tables 2 and 3).
In African Americans, the rare G230S variant allele appeared to be more common in ischemic
stroke cases (2.6%) and CHD cases (1.8%) compared to non-cases (1.2%) (Table 2). One
individual carrying the G230S variant allele experienced a stroke and CHD event on separate
occasions. When considering the composite end point, the G230S variant allele was associated
with higher risk of an incident ischemic stroke or CHD event after covariate adjustment (model
2, HRR 8.37, 95% CI 1.53–45.8, P = 0.014). No relationship between the R8W, P17L, R53H, or
L237M variant alleles and risk of either end point was observed (Table 2).
PTGS2 polymorphisms
In African Americans, the variant −765C allele was significantly more common among
ischemic stroke cases compared to cohort random sample non-cases (61.4 versus 49.4%,
respectively, P = 0.032) (Table 2). Presence of at least one −765C allele was associated with
significantly higher risk of incident ischemic stroke events relative to −765G homozygotes
after covariate adjustment (model 2, HRR 1.76, 95% CI 1.05–2.94, P = 0.031, q = 0.146) (Table
3). This relationship was not modified by gender (interaction P = 0.645). The −765C allele
was not significantly associated with risk of ischemic stroke in Caucasians, or risk of CHD in
either Caucasians or African Americans (Tables 2 and 3). No relationship between the
V511A variant allele and risk of either end point was observed (Table 2).
Aspirin utilization
In Caucasians, aspirin utilization at baseline appeared to modify the relationship between the
G-765C polymorphism in PTGS2 and risk of incident CHD events (interaction P = 0.072, q =
0.137) (Table 4); however, the interaction was not statistically significant. When stratified by
aspirin use at baseline, the variant −765C allele demonstrated a nonsignificant association with
higher risk of CHD in aspirin non-users (model 2, HRR 1.36, 95% CI 0.97–1.90, P = 0.075)
and lower risk of CHD in those reporting aspirin use (model 2, HRR 0.60, 95% CI 0.36–1.02,
P = 0.058). Moreover, similar results were obtained after restriction to only those reporting
aspirin use or no aspirin use at both their baseline and first follow-up visit (interaction P =
0.047, q = 0.137) (Table 4). Aspirin utilization at baseline did not modify the relationship
between the G-765C polymorphism and risk of ischemic stroke (interaction P = 0.639), or the
relationship between the G-1006A polymorphism in PTGS1 and risk of either ischemic stroke
(interaction P = 0.254) or CHD (interaction P = 0.965).
PTGS1 G-1006A urinary biomarker analysis
Participants with one (G/A) or two (A/A) copies of the PTGS1 variant −1006A allele had lower
urinary 11-dehydrothromboxane (Tx)B2 concentrations compared to wild-type (G/G)
individuals (G/G: 0.58±0.17 ng/mg versus G/A or A/A: 0.33±0.06 ng/mg creatinine; P = 0.133)
(Figure 1). These differences were most pronounced and statistically significant in Caucasians
(G/G: 0.94±0.27 ng/mg versus G/A or A/A: 0.38±0.09 ng/mg creatinine; P = 0.023); however,
no differences were observed in African Americans (G/G: 0.21±0.09 ng/mg versus G/A or A/
A: 0.24±0.04 ng/mg creatinine; P = 0.763). Similar results were observed in the adjusted
analysis (Figure 1b). No significant differences in urinary 2,3-dinor-6-keto-PGF1α
concentrations were observed across G-1006A genotype in either Caucasians (P = 0.867) or
African Americans (P = 0.799) (Supplementary Materials).
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Our analysis demonstrated that genetic variation in PTGS1 and PTGS2 was associated with
risk of incident ischemic cardiovascular disease events in Caucasians and African Americans
enrolled in the ARIC study. Specifically, the variant −1006A allele in PTGS1 and −765C allele
in PTGS2 were associated with higher risk of ischemic stroke events in Caucasians and African
Americans, respectively. Moreover, the rare G230S variant allele in PTGS1 appeared to be
associated with higher risk of ischemic stroke and CHD events in African Americans. Although
the G-765C polymorphism in PTGS2 was not significantly associated with CHD incidence,
aspirin utilization appeared to modify this relationship in Caucasians. Collectively, our findings
suggest that genetic variation in PTGS1 and PTGS2 may be important modifiers of
cardiovascular disease risk in humans; however, these putative relationships remain
exploratory until confirmed in an independent population.
COX-derived prostaglandins are important regulators of cardio- and cerebrovascular disease
risk in vivo.2–5 For instance, the balance between TxA2 and prostacyclin (PGI2) significantly
modifies atherosclerotic lesion development.7 Moreover, preferentially inhibiting COX-1-
derived TxA2 in platelets via low-dose aspirin administration reduces the risk of myocardial
infarction, ischemic stroke, and death in high-risk patients.5 In contrast, selective COX-2
antagonists inhibit endothelial PGI2 biosynthesis without influencing platelet TxA2 production
and increase risk of CHD events, particularly in high-risk patients.3,4 Selective inhibition of
COX-1 significantly reduces cerebral blood flow and vasodilatory responses, and COX-1−/−
mice have larger cerebral infarct volumes compared to wild-type mice after middle cerebral
artery occlusion.17,18 Moreover, cerebral COX-1 gene transfer before middle cerebral artery
occlusion reduces cerebral infarct volume in rats.19 Selective inhibition of COX-2 also
abolishes cerebral vasodilatory responses.20 However, COX-2−/− mice have significantly
smaller infarct volumes compared to wild-type mice after middle cerebral artery occlusion,
21 and transgenic mice with neuronal overexpression of COX-2 have larger infarct volumes,
implicating the post-ischemic inflammatory effects of increased COX-2 expression in brain
injury.22 Collectively, preclinical and clinical evidence demonstrates the importance of
COX-1 and COX-2 in the pathogenesis of ischemic stroke and CHD. Consequently, genetic
variation in PTGS1 and PTGS2 may be important modifiers of cardiovascular disease
susceptibility.
The variant −1006A allele in PTGS1 was associated with higher risk of incident ischemic stroke
events in Caucasians in the ARIC study. This polymorphism is one of seven variants within
the PTGS1 5′ untranslated region present in substantial LD;12 however, the functional
relevance of this haplotype had not been well characterized to date. Our biomarker analysis
demonstrated that Caucasian variant −1006A allele carriers had significantly lower urinary 11-
dehydro-TxB2 levels, indicative of lower COX-1 metabolic activity. Although lower platelet
TxA2 production would be hypothesized to lower risk of ischemic stroke events, urinary levels
of its stable 11-dehydro-TxB2 metabolite may represent a biomarker of COX-1 metabolic
activity across various cell types, including the cerebral vasculature. As described, lower
COX-1 activity impairs cerebral blood flow and enhances ischemic brain injury in preclinical
models.17,18 Consequently, our analysis could suggest that variant −1006A allele carriers have
lower COX-1 metabolic activity, providing a potential mechanistic explanation for the
observed relationship between the −1006A allele and higher risk of incident ischemic stroke
events in Caucasians. Owing to the known LD structure within the PTGS1 5′ untranslated
region, the G-1006A polymorphism may not be the functionally relevant locus driving the
observed associations. The G-1006A polymorphism was in near-perfect LD with the P17L
polymorphism in Caucasians, consistent with our previous findings,12 and the reconstructed
haplotype containing both the variant −1006A and P17L alleles demonstrated an association
with higher ischemic stroke risk similar to that observed with the variant −1006A allele alone.
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Although the P17L variant has normal basal COX-1 metabolic activity in vitro,12 the lack of
an association between the G-1006A polymorphism and both urinary 11-dehydro-TxB2 levels
and ischemic stroke risk in African Americans could be due to the lack of LD with the P17L
polymorphism and/or other genetic and environmental factors not accounted for in our analysis.
Confirmation of these findings in an independent population and additional mechanistic studies
characterizing the functional effects of this variant haplotype are necessary.
The rare G230S variant allele in PTGS1, which is monomorphic in Caucasians, appeared to be
associated with higher risk of ischemic cardiovascular events in African Americans. The
G230S variant has significantly lower COX-1 metabolic activity in vitro compared to wild-
type enzyme, and molecular modeling suggests that this variant may disrupt the active
conformation of COX-1.12 Association between the G230S variant allele and higher ischemic
stroke incidence is also consistent with preclinical data, implicating the protective role of
COX-1 in cerebrovascular function.17–19 Owing to the rare frequency of the G230S variant
allele and subsequent fewer incident events than covariates included in the regression analysis,
the observed association carried wide CIs and should be interpreted with caution.
A significant association between the variant −765C allele in PTGS2 and higher risk of
ischemic stroke incidence was observed in African Americans. This variant disrupts an Sp1
binding site in the PTGS2 proximal promoter, reduces COX-2 transcription and expression,
and consequently carries significant anti-inflammatory effects.9,13–15,23 The −765C allele
was previously associated with lower risk of prevalent myocardial infarction or ischemic stroke
in a high-risk Italian population,15 contrasting epidemiological and clinical trial evidence
demonstrating associations between selective COX-2 inhibitor use and increased risk of
cardiovascular events.3,4 Although preclinical evidence suggests that selective COX-2
inhibition abolishes cerebral vasodilatory responses,20 lower COX-2 expression also reduces
the extent of ischemic brain injury after a cerebral infarct.21 Future studies evaluating the
influence of the G-765C polymorphism on prognosis after stroke events appear necessary. A
subsequent analysis from the Physicians’ Health Study demonstrated no significant
relationship between the −765C allele and risk of either myocardial infarction or ischemic
stroke.24 No significant association between the −765C allele and risk of incident CHD events
was observed in the ARIC study. However, aspirin utilization may have modified this
relationship in Caucasians, such that the −765C allele appeared to be associated with higher
CHD risk in aspirin non-users and lower risk in those reporting aspirin use. This observation
would be consistent with the hypothesis that concomitant aspirin utilization mitigates the
cardiovascular hazard associated with selective COX-2 inhibition via restoration of PGI2-
TxA2 balance.3 Presence of a gene–aspirin interaction could help explain, at least in part, the
association between the −765C allele and lower cardiovascular risk observed by Cipollone et
al.15 This analysis targeted a high-risk population and 67% were receiving aspirin therapy.
15 Perhaps aspirin use in −765C allele carriers could help restore PGI2-TxA2 balance, allow
the plaque stabilizing effects related to suppression of COX-2-mediated PGE2 synthesis to
predominate,15 and result in lower risk of CHD events. However, due to the power limitations
in our interaction analysis, these hypothesis-generating findings must be interpreted with
caution and confirmed in larger populations. Future studies evaluating the mechanisms
underlying this potential pharmacogenetic interaction will also be necessary, particularly as
recent evidence suggests that the G-765C polymorphism does not influence celecoxib-
mediated suppression of PGE2 biosynthesis.25
Although our study evaluated rigorously ascertained incident events, we are unable to elucidate
mechanisms underlying the observed associations. We also recognize the limitations related
to the evaluation of aspirin utilization at baseline in an observational study. Patients were not
randomized at baseline, and aspirin therapy was likely initiated in those at highest risk of
cardiovascular events. We attempted to adjust for potential confounders in our regression
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analysis; however, additional factors such as misclassification bias, changes in aspirin
utilization throughout follow-up, duration of therapy, and dose could have influenced our
results. In order to enhance our confidence that participants reporting aspirin use at baseline
were on a stable regimen, most likely for primary prevention, we repeated the interaction
analysis after restriction to only those reporting aspirin use or no aspirin use at both their
baseline and first follow-up visit. Similar results were obtained, enhancing our confidence in
the observed putative interaction. However, these findings should be considered exploratory
and hypothesis generating until confirmed in a larger population. Moreover, even though the
ARIC study is one of the largest biethnic cohorts assembled for the evaluation of incident
cardiovascular disease risk, our gene association analysis also carried limitations in statistical
power. For the PTGS1 G-1006A and PTGS2 G-765C polymorphisms, we estimated that greater
than 80 and 90% power was present to detect an HRR of 2.0 for the stroke and CHD end points,
respectively, in both Caucasians and African Americans (Supplementary Materials). However,
substantially less power was present to detect an HRR of 1.5, which may represent a more
plausible magnitude for an association between a genetic polymorphism and risk of a complex,
polygenic disease.
We also acknowledge that it may be difficult to gauge the statistical significance of our findings
considering the number of comparisons completed. Consequently, we assessed the false
discovery rate across all completed tests in our association analysis. Although no gold-standard
q-value threshold has been established to identify “true” associations, incorporation of this
statistical approach into candidate gene association studies has become an increasingly
recognized method to account for multiple comparisons and to enhance confidence in observed
associations.26 As q-values related to the association between the G-1006A (Caucasians) and
G-765C (African Americans) polymorphisms and ischemic stroke risk were estimated to be
<0.15, we have a higher level of confidence in our reported findings. However, validation in
a well-powered, independent population will be ultimately necessary to confidently conclude
that genetic variation in PTGS1 and PTGS2 is significantly associated with cardiovascular
disease susceptibility. Moreover, molecular, biochemical, and physiological studies will also
be necessary to elucidate the mechanisms underlying the observed associations.
METHODS
Study population
Participants were selected from the ARIC study, a longitudinal, population-based cohort study
of 15,792 men and women aged 45–64 years from four US communities (Forsyth County, NC;
Jackson, MS; Minneapolis, MN; and Washington County, MD) enrolled between 1987 and
1989.27 Since enrollment, participants have been followed prospectively via annual phone
interviews, clinic examinations approximately every 3 years through 1998, and ongoing
abstraction of hospital and death certificate records. The study protocol was approved by the
Institutional Review Board of each center, and consent was obtained from each participant.
Ascertainment of incident CHD and stroke cases
All incident cases that occurred between baseline and December 31, 1998 were evaluated
(median follow-up 9.1 years), excluding participants with a history of a physician-diagnosed
CHD or stroke event at baseline. Incident CHD (n = 1,085) was defined as (1) definite or
probable myocardial infarction (n = 520), (2) electrocardiographic evidence of silent
myocardial infarction (n = 112), (3) definite CHD death (n = 110), or (4) coronary
revascularization procedure (n = 343). Incident stroke was defined as a definite or probable
ischemic stroke (n = 300). Of note, n = 68 individuals experienced an incident CHD and
ischemic stroke event on separate occasions.
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The ascertainment of cases and criteria for classification have been described previously.28,
29 All potential events were systematically reviewed and adjudicated by the ARIC Morbidity
and Mortality Classification Committee.27–29 Briefly, hospitalized myocardial infarction was
classified as definite or probable based on chest pain symptoms, cardiac enzyme levels, and
electrocardiographic changes. Definite CHD death was classified based on chest pain
symptoms, underlying cause of death, hospitalization records, and medical history. Coronary
revascularization procedures included coronary artery bypass grafting and percutaneous
coronary intervention. Using the National Survey of Stroke criteria,30 a stroke event was
classified as definite or probable if there was (1) rapid onset of neurological symptoms that
lasted >24 h or led to death within 24 h; (2) no evidence of pathology that could have mimicked
stroke; and (3) one major (e.g., aphasia or hemiparesis) or two minor (e.g., diplopia or
dysarthria) neurological deficits. Qualifying cases were further classified as ischemic
(thrombotic brain infarction, cardioembolic stroke) or hemorrhagic (subarachnoid hemorrhage,
intracerebral hemorrhage) on the basis of neuroimaging studies and autopsy, when available.
29
Baseline measurements
Detailed demographic, clinical, and biochemical data were obtained from each participant at
baseline, as described.31 Race was self-reported. Aspirin utilization (yes/no), including
aspirin-containing products, was assessed through a detailed medication history at baseline and
each follow-up visit.32 Dose and duration of use were not determined.
Cohort random sample
A random sample of all ARIC participants without history of CHD or stroke at baseline was
assembled to serve as the reference group for the case–cohort comparisons (n = 1,065). Of
note, n = 85 and n = 29 of these individuals became incident CHD and stroke cases, respectively,
during follow-up. Sampling of the cohort was stratified on age (⩾55 or <55 years), gender,
and race (Caucasian or African American). Sampling proportions varied across each stratum.
Genotyping
Available genomic DNA from all incident CHD (n = 1,023) and ischemic stroke cases (n =
270) and non-cases in the cohort random sample (n = 919) was genotyped for the G-1006A,
R8W, P17L, R53H, G230S, and L237M polymorphisms in PTGS1 and the V511A
polymorphism in PTGS2 using multiplex matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry methods (Sequenom, San Diego, CA), as described (Supplementary
Materials).33 As matrix-assisted laser desorption/ionization time-of-flight methods were
unsuccessful, the G-765C polymorphism in PTGS2 was genotyped using the BeadArray
system (Illumina, San Diego, CA), as described.34 Blind replicates were included for quality
control for both methods, and fewer than 5% of individuals had missing genotype data.
These polymorphisms were identified from our resequencing effort as part of the NIEHS
Environmental Genome Single Nucleotide Polymorphism program (https://dir-
apps.niehs.nih.gov/egsnp/home.htm) and/or the published literature (Table 1) to include the
most frequent promoter/5′ untranslated region or non-synonymous polymorphisms identified
to date in each gene.8–13,15 The G-1006A polymorphism is one of seven frequent
polymorphisms in the 5′ untranslated region of PTGS1 present in significant LD and on the
same haplotype in both European/Caucasian (D′ = 1.0, r2 = 0.73–1.0) and African (D′ = 1.0,
r2 = 1.0) individuals.12 The G-1006A polymorphism was selected to capture variation at each
of these loci. The other selected polymorphisms in PTGS1 include infrequent variants with
known functional relevance (R53H, G230S, L237M) and the most frequent non-synonymous
variants identified to date (R8W, P17L).10–12 In PTGS2, the G-765C polymorphism was
selected, as this polymorphism is frequent and functionally relevant.9,13,15 The other selected
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polymorphism in PTGS2 (V511A) is the most frequent non-synonymous variant identified to
date.8
Urinary biomarker analysis
Urine from the most recent clinic visit was obtained from 33 participants selected based on
their PTGS1 G-1006A genotype (G/G (n = 12), G/A (n = 10), A/A (n = 11)), and matched based
on age, gender, race, and aspirin/non-steroidal use. In order to evaluate the functional relevance
of this polymorphism, systemic biosynthesis of TxA2 and PGI2 was assessed by measurement
of their stable urinary metabolites, 11-dehydro-TxB2 and 2,3-dinor-6-keto-PGF1α,
respectively, using gas chromatography-mass spectrometry methods, as described.35,36
Data analysis
Inverse sampling fractions from each stratum were used as weights in estimation of adjusted
covariate means and proportions by linear and logistic regression, respectively. Cohort random
sample allele frequencies were evaluated for deviation from Hardy–Weinberg equilibrium, and
pairwise LD statistics were calculated (Haploview 3.3).37 HRRs and 95% CIs for the
development of incident CHD or ischemic stroke in relation to genotype were calculated by
weighted proportional hazards regression, using Barlow’s method to account for the stratified
random sampling and case–cohort design.38 Model 1 included baseline age, gender, and study
center as covariates. Model 2 also included significant clinical covariates, which were current
smoking status, diabetes, hypertension, high-density lipoprotein cholesterol, total cholesterol,
and body mass index at baseline for the CHD end point, and current smoking status, diabetes,
and hypertension for the stroke end point. Assuming an autosomal-dominant mode of
inheritance, individuals with one or two variant alleles were combined for comparison to wild-
type individuals. This assumption was based on previous studies demonstrating significant
functional effects of the PTGS2 G-765C polymorphism in individuals carrying one or two
variant alleles,9,13,15 and our current urinary 11-dehydro-TxB2 biomarker analysis with the
PTGS1 G-1006A polymorphism (Figure 1). All analyses were completed separately in
Caucasians and African Americans.
Interaction testing was completed on a multiplicative scale between baseline aspirin utilization
(yes/no) and both G-1006A (PTGS1) and G-765C (PTGS2) genotype for both end points in
Caucasians, using a Wald χ2 test for significance of the estimated β-coefficient for the
interaction term.39 Stratified weighted proportional hazards regression was also completed to
further explore potential interactions. Gene–aspirin interaction testing was not completed in
African Americans because of low aspirin utilization and sample size limitations.
To minimize the impact of the multiple statistical tests conducted and to enhance our confidence
in the conclusions drawn from the observed associations, we estimated the false discovery rate
q-value of our findings, separately for each end point, which is defined as the expected
proportion of statistical tests deemed significant that are actually false-positives (QVALUE).
40 We considered statistical tests from the unadjusted, model 1 and model 2 association
analyses for each PTGS1 and PTGS2 polymorphism. Additional q-value estimates were also
calculated for the gene–aspirin interaction analysis. Only q-values for statistically significant
findings are presented.
Urinary 11-dehydro-TxB2 and 2,3-dinor-6-keto-PGF1α concentrations were compared across
G-1006A genotype by analysis of variance. All data are normalized to milligrams of urinary
creatinine, and presented as mean±SEM. These comparisons were repeated after adjusting for
age, gender, race, PTGS2 G-765C genotype, CHD/stroke case status, and aspirin/non-steroidal
use at the time of sample collection, using least squares regression.
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(a) Unadjusted and (b) adjusted mean±SEM urinary 11-dehydro-TxB2 concentrations,
normalized to milligrams of urinary creatinine (Cr), are presented according to G-1006A
genotype as wild-type (G/G) (black bars) and variant (G/A or A/A) (white bars). Data are
presented separately for all participants (All, n = 33) and stratified by race (Cauc = Caucasians,
n = 20; AA = African Americans, n = 13). *P<0.05 versus wild type. The values presented in
b were adjusted for age, gender, race, PTGS2 G-765C genotype, CHD or stroke case status,
and aspirin/non-steroidal use at the time of sample collection, using least squares regression.
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